Omaha Insomnia and Psychiatric Services

What Omaha Insomnia and Psychiatric Services does

Omaha Insomnia and Psychiatric Services LLC is a privately-held, physician-led mental health practice founded in 2013 and headquartered at 13917 Gold Circle in Omaha, Nebraska. The clinic operates a comprehensive psychiatry and behavioral health service line including medication management, individual and group therapy, forensic psychiatric evaluations, surgical-clearance assessments, home sleep studies, and an in-house Clinical Research Department running trials in bipolar disorder, schizophrenia, tardive dyskinesia, and major depressive disorder. Its core clinical differentiation sits in the neuromodulation and pharmacogenomic stack it has assembled: FDA-cleared BrainsWay deep Transcranial Magnetic Stimulation (TMS), surgically implanted Vagus Nerve Stimulation (VNS) for treatment-resistant depression, Janssen's Spravato (esketamine) nasal spray administered under REMS, and Myriad Genetics' GeneSight pharmacogenomic testing to guide medication selection. Patient access is supported through same-day and next-day scheduling, evening and Saturday hours, virtual appointments, and partner locations at VEN Healthcare in Council Bluffs, Iowa and Lincoln, Nebraska, with Associates for Psychiatric Services as a referral affiliate.

The business model is fee-for-service healthcare delivery billed through commercial insurance, with prior authorization handled internally. The clinic is in-network with major payers including Cigna, United Healthcare, Aetna, and BlueCross BlueShield. A secondary revenue stream comes from pharmaceutical-sponsored clinical research, where sponsors compensate the practice for trial conduct and provide study medication and devices at no cost to participants. An on-site Genoa Pharmacy co-located at the Omaha headquarters supports medication dispensing and adherence. The practice operates as a private LLC with 16 employees, no public listing, no disclosed venture or private-equity backing, and no subsidiaries or acquired entities. Customer acquisition relies on provider referrals, self-referral through online patient registration forms, and earned media (KETV news features and Dr. Vithyalakshmi Selvaraj's media presence). Payer mix concentration across four major national insurers is the key structural revenue dependency; no individual patient or institutional customer represents a material share of revenue.

Name

Omaha Insomnia and Psychiatric Services

Legal name

Omaha Insomnia And Psychiatric Services LLC

Website

https://omahainsomnia.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Omaha Insomnia and Psychiatric Services is a private, physician-led psychiatric practice in Omaha, Nebraska, founded in 2013, delivering medication management, therapy, forensic evaluations, and FDA-cleared advanced treatments — TMS, VNS, Spravato, and GeneSight testing — to adults and adolescents with treatment-resistant mental health conditions across Nebraska and western Iowa.

Ownership category

akta.pro rank

Product category

Psychiatric and Mental Health Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industries

Outpatient Mental Health & Counseling Clinics (HLAFABAC), Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Psychiatric medication management
• Transcranial magnetic stimulation
• Mental health services
• Forensic psychiatric evaluations
• Clinical research trials

Headquarters

HQ city

Omaha

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Healthcare Services Billing: Fee-for-service revenue from psychiatric consultations, medication management, therapy services, diagnostic testing, and specialized treatments such as TMS, VNS, and Spravato. Billable through insurance with prior authorization processes.
2. Clinical Research: Revenue from pharmaceutical clinical trials and research studies. Participants receive compensation, study medication and devices at no cost, generating revenue through research sponsors and grants.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Omaha Insomnia and Psychiatric Services is a private psychiatric practice founded in 2013 in Omaha, Nebraska that diagnoses and manages medication for psychiatric disorders including depression, anxiety, insomnia, mood disorders, PTSD, and psychosis. The clinic delivers a comprehensive suite of services including advanced neuromodulation treatments (Transcranial Magnetic Stimulation, Vagus Nerve Stimulation), Spravato (esketamine) therapy, pharmacogenomic (GeneSight) testing, individual/group/family/couples therapy, forensic psychiatric evaluations, home sleep studies, surgical clearance evaluations, and an active clinical research department running pharmaceutical trials. Services are delivered via in-person and virtual appointments with same-day or next-day availability, evening hours, and Saturday appointments.

Product overview

Omaha Insomnia and Psychiatric Services is a mental health care practice established in 2013 offering a comprehensive suite of psychiatric and therapeutic services. The clinic provides medication management, advanced neuromodulation treatments (TMS, VNS), Spravato for treatment-resistant depression, psychogenetic testing (GeneSight), therapy services, forensic evaluations, sleep studies, and surgical clearance evaluations. The practice also operates an active clinical research department conducting trials for schizophrenia, bipolar disorder, tardive dyskinesia, and depression. Services are available via virtual and in-person appointments with same-day or next-day availability.

Differentiator

Problem solved

Functional benefit

Products and services

• Medication Management Psychiatric medication management services including diagnosis and individually tailored medication regimens for conditions such as depression, anxiety, insomnia, mood disorder, PTSD, and psychosis. Provided by psychiatrists, nurse practitioners, and physician assistants.
• Transcranial Magnetic Stimulation (TMS) FDA-cleared, non-invasive procedure using magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression when medications fail. Uses Brainsway deep TMS technology and is covered by insurance with prior authorization.
• Vagus Nerve Stimulation (VNS) FDA-approved treatment using gentle electrical pulses to stimulate the vagus nerve for treatment-resistant depression. Involves surgical implantation of a pulse generator device in the chest.
• Spravato (Esketamine) Treatment FDA-approved esketamine nasal spray medication used along with an oral antidepressant to treat adults with treatment-resistant depression and depressive symptoms in adults with major depressive disorder who have suicidal thoughts or actions.
• Psychogenetic Testing (GeneSight) Pharmacogenomic test analyzing clinically important genetic variations that may affect medication response, helping clinicians determine which psychiatric medications are more likely to work and identifying those requiring dose adjustments or with increased side effect risks.
• Therapy Services Individual therapy, group therapy, family counseling, couples counseling, and substance use and abuse treatment provided by licensed therapists (LCSW, LIMHP, PLMHP) and psychologists (PhD).
• Forensic Psychiatric Evaluations Legal-related psychiatric evaluations including child custody, drug/alcohol assessments, sexual perpetrator evaluations, juvenile offenses, capacity evaluations, guardianship, parental rights, immigration, social security disability, workman's compensation, and personal injury assessments.
• Home Sleep Study Diagnostic home sleep study service for evaluating sleep apnea and its effects on physical and mental health, complementing the mental health treatment offering.
• Surgical Clearance Evaluation Pre-surgical psychiatric evaluations for procedures including spinal cord stimulator, bariatric surgery, dorsal root ganglion stimulation, and organ transplant clearance.
• Clinical Research Department Pharmaceutical clinical trials and research studies evaluating treatment outcomes and safety for mental health disorders including bipolar disorder, schizophrenia, tardive dyskinesia, and major depressive disorder. Participants receive compensation, study medication, and devices at no cost.

Quantifiable outcome

• Patients report improved depression symptoms after TMS treatment

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• VEN Healthcare Council BluffscoreChannel Partner/ Reseller/ DistributorPartner healthcare location providing psychiatric services. Patients can access care at this location through referral or scheduling.
• VEN Healthcare LincolncoreChannel Partner/ Reseller/ DistributorPartner healthcare location providing psychiatric services in the Lincoln area. Extends geographic reach of services.
• Associates for Psychiatric Services PCminorChannel Partner/ Reseller/ DistributorAssociated psychiatric services provider referenced on the clinic's website for patient referrals.
• Genoa PharmacycoreStrategic or Co-development PartnerOn-site pharmacy co-located at 13917 Gold Cir Suite P, open 8:30 AM to 5:00 PM. Provides convenient prescription fulfillment for patients. Accepts debit cards, credit cards, cash and check.
• GeneSight (Myriad Genetics)coreTechnology or IntegrationPharmacogenomic testing service used to analyze genetic variations affecting medication response. Results help determine which medications may work better or have increased side effect risks.
• BrainswaycoreTechnology or IntegrationManufacturer of Transcranial Magnetic Stimulation (TMS) equipment used at the clinic. Brainsway's deep TMS technology is FDA-cleared for treating depression.
• Spravato (Janssen Pharmaceuticals)coreTechnology or IntegrationFDA-approved esketamine nasal spray medication for treatment-resistant depression and MDD with suicidal thoughts. Administered at the clinic alongside oral antidepressants.
• CignacoreOthersMajor health insurance provider accepted by the clinic for covered services including TMS treatment with prior authorization.
• United HealthcarecoreOthersMajor health insurance provider accepted by the clinic for covered mental health services.
• AetnacoreOthersMajor health insurance provider accepted by the clinic for covered mental health services.
• BlueCross BlueShieldcoreOthersMajor health insurance provider accepted by the clinic for covered mental health services including TMS.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Cerebral: Digital-first mental health platform offering medication management and therapy online. Partial overlap with Omaha Insomnia's outpatient psychiatry and virtual appointment offering; differs in being primarily telehealth-only rather than clinic-anchored.

Direct peers

• Array Behavioral Care: Outpatient telepsychiatry and in-person behavioral health provider serving patients and partner organizations across multiple states. Comparable to Omaha Insomnia's hybrid virtual/in-person psychiatry model and broad insurance participation.
• Talkiatry: Outpatient psychiatry group with in-person and telehealth services staffed by psychiatrists, focused on medication management across multiple U.S. states. Directly comparable to Omaha Insomnia's psychiatrist-led, insurance-based, hybrid in-person/virtual outpatient psychiatry model.
• Amen Clinics: Multi-site outpatient psychiatry practice combining medication management with advanced diagnostics (SPECT imaging, pharmacogenomics) and TMS. Comparable to Omaha Insomnia in offering integrated advanced-treatment modalities under a specialist-led, regional clinic model.
• Mindpath Health: Multi-state outpatient mental health group providing psychiatry, therapy, and TMS across clinics and via telehealth. Comparable as a regional-to-multi-state outpatient psychiatry operator offering both medication management and advanced neuromodulation.
• Greenbrook TMS: National outpatient provider focused on Transcranial Magnetic Stimulation for depression and other mental health conditions. Directly comparable to Omaha Insomnia's TMS-centric, multi-site outpatient psychiatry model and use of FDA-cleared TMS technology for treatment-resistant depression.
• Apollo Behavioral Health: Outpatient psychiatric practice group offering medication management, TMS, Spravato, and therapy across multiple locations. Highly comparable to Omaha Insomnia's treatment-resistant depression focus and advanced-modality outpatient service mix.

Broad incumbents

• McLean Hospital: Major psychiatric hospital affiliated with Harvard offering inpatient and outpatient specialty mental health services including TMS, Spravato, and research. Overlaps as an established provider of advanced psychiatric treatments but at hospital scale and academic scope rather than community-clinic scale.
• LifeStance Health: Large publicly-traded outpatient mental health platform offering psychiatry, psychotherapy, and advanced treatments across dozens of U.S. markets. Comparable as a scaled outpatient mental health provider; broader portfolio than Omaha Insomnia but overlapping patient base and service mix including TMS and Spravato administration.
• Sheppard Pratt: Large nonprofit behavioral health system providing inpatient, outpatient, and specialty psychiatric services across Maryland. Comparable in offering comprehensive outpatient psychiatric services including TMS and medication management, but at substantially larger institutional scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/omahainsomnia

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omaha Insomnia and Psychiatric Services